<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2013.2811</article-id>
<article-id pub-id-type="publisher-id">or-31-01-0117</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>WEI</given-names></name><xref rid="af1-or-31-01-0117" ref-type="aff">1</xref><xref rid="fn1-or-31-01-0117" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>LIU</surname><given-names>MIN</given-names></name><xref rid="af1-or-31-01-0117" ref-type="aff">1</xref><xref rid="fn1-or-31-01-0117" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>XU</surname><given-names>YUN-FEI</given-names></name><xref rid="af1-or-31-01-0117" ref-type="aff">1</xref><xref rid="fn1-or-31-01-0117" ref-type="author-notes">&#x0002A;</xref></contrib>
<contrib contrib-type="author">
<name><surname>FENG</surname><given-names>YUAN</given-names></name><xref rid="af2-or-31-01-0117" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHE</surname><given-names>JIAN-PING</given-names></name><xref rid="af1-or-31-01-0117" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>WANG</surname><given-names>GUANG-CHUN</given-names></name><xref rid="af1-or-31-01-0117" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>ZHENG</surname><given-names>JUN-HUA</given-names></name><xref rid="af1-or-31-01-0117" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-or-31-01-0117"/></contrib></contrib-group>
<aff id="af1-or-31-01-0117">
<label>1</label>Department of Urology, Shanghai Tenth People&#x02019;s Hospital, Tongji University, Shanghai 200072, P.R. China</aff>
<aff id="af2-or-31-01-0117">
<label>2</label>Department of Nephrology, Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu 210093, P.R. China</aff>
<author-notes>
<corresp id="c1-or-31-01-0117">Correspondence to: Professor Jun-Hua Zheng, Department of Urology, Shanghai Tenth People&#x02019;s Hospital, Tongji University, 301 Yanchang Road, Shanghai 200072, P.R. China, E-mail: <email>kidneyliu@163.com</email></corresp><fn id="fn1-or-31-01-0117">
<label>&#x0002A;</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="ppub">
<month>1</month>
<year>2014</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>10</month>
<year>2013</year></pub-date>
<volume>31</volume>
<issue>1</issue>
<fpage>117</fpage>
<lpage>124</lpage>
<history>
<date date-type="received">
<day>05</day>
<month>09</month>
<year>2013</year></date>
<date date-type="accepted">
<day>07</day>
<month>10</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014, Spandidos Publications</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>Quercetin and hyperoside (QH) in combination (1:1 ratio) have previously been shown to inhibit the growth of human leukemia cells. Here, we investigated the anticancer activity of the same mixture in 786-O renal cancer cells. QH decreased the generation of reactive oxygen species (ROS) by up to 2.25-fold and increased the antioxidant capacity by up to 3-fold in 786-O cells (3.8&#x02013;60 <italic>&#x003BC;</italic>g/ml), whereas IC<sub>50</sub> values for viability were 18.2, 18.7 and 11.8 <italic>&#x003BC;</italic>g/ml, respectively. QH also induced caspase-3 cleavage (2-fold) and increased PARP cleavage. Specificity protein (Sp) transcription factors are overexpressed in cancer cells and regulate genes required for cell proliferation, survival and angiogenesis. QH treatment decreased the expression of Sp1, Sp3 and Sp4 mRNA and this was accompanied by decreased protein expression. Moreover, expression of the Sp-dependent anti-apoptotic survival gene survivin was also significantly reduced, both at the mRNA and protein levels. QH decreased microRNA-27a (miR-27a) and induced the zinc finger protein ZBTB10, an Sp-repressor, suggesting that interactions between QH and the miR-27a-ZBTB10 axis play a role in Sp downregulation. This was confirmed by transfection of cells with a specific mimic for miR-27a, which partially reversed the effects of QH. These findings are consistent with previous studies on botanical anticancer agents in colon cancer cells.</p></abstract>
<kwd-group>
<kwd>renal cancer</kwd>
<kwd>quercetin</kwd>
<kwd>hyperoside</kwd>
<kwd>microRNA-27a</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Renal cell carcinoma (RCC) is the most lethal urologic tumor and the sixth leading cause of cancer-related mortality in Western countries. Each year, approximately 200,000 patients are diagnosed with this malignancy resulting in approximately 100,000 deaths, and its incidence has steadily increased in the last decades (<xref rid="b1-or-31-01-0117" ref-type="bibr">1</xref>&#x02013;<xref rid="b3-or-31-01-0117" ref-type="bibr">3</xref>). At present, the most effective treatment for localized RCC is surgical resection; however, 30&#x00025; of patients develop metastatic disease after surgery, and the median survival for these patients is only 13 months. Therefore, novel therapeutic strategy as well as prophylactic regimens are urgently required.</p>
<p>Prevention of numerous types of cancer through a diet rich in fruits and vegetables has been in part attributed to plant-derived botanicals, including polyphenolics, which may protect against various chronic degenerative diseases such as cancer or cardiovascular disease (<xref rid="b4-or-31-01-0117" ref-type="bibr">4</xref>). Quercetin is a dietary flavonoid found in tea, onion, grapes, wines and apples, and the anticancer activities of quercetin have been assessed in several cancer cell lines, as well as <italic>in vivo</italic>(<xref rid="b5-or-31-01-0117" ref-type="bibr">5</xref>,<xref rid="b6-or-31-01-0117" ref-type="bibr">6</xref>). Hyperoside is a stilbene analog and a phytoalexin produced by plants as a defense mechanism in response to fungal diseases, stress and UV radiation; the primary dietary sources of hyperoside are <italic>Malus micromalus</italic> and abelmosk (<xref rid="b7-or-31-01-0117" ref-type="bibr">7</xref>). Hyperoside was found to exhibit anticancer properties by inhibiting cell proliferation, inducing apoptosis, decreasing angiogenesis, and causing cell cycle arrest in several cancer cell lines (<xref rid="b8-or-31-01-0117" ref-type="bibr">8</xref>). A combination of quercetin and hyperoside (QH) previously exhibited synergistic interactions in their anticancer effects on MOLT-4 leukemia cells (<xref rid="b9-or-31-01-0117" ref-type="bibr">9</xref>). In a study with mouse skin tumors, a combination of hyperoside with tea polyphenolics demonstrated synergistic anticancer effects (<xref rid="b10-or-31-01-0117" ref-type="bibr">10</xref>). In pancreatic cancer stem cells, sulforaphane was found to synergize with quercetin in the inhibition of the self-renewal of cells (<xref rid="b11-or-31-01-0117" ref-type="bibr">11</xref>). Quercetin and epigallocatechin gallate (EGCG) synergistically inhibited invasion, migration and epithelial-mesenchymal transition in prostate cancer stem cells (<xref rid="b12-or-31-01-0117" ref-type="bibr">12</xref>).</p>
<p>Increasing evidence suggests that specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 are overexpressed in tumors and regulate genes important for cancer cell death and survival (<xref rid="b13-or-31-01-0117" ref-type="bibr">13</xref>,<xref rid="b14-or-31-01-0117" ref-type="bibr">14</xref>). More recently, the involvement of microRNA-27a (miR-27a) in the regulation of Sp1 transcription factor through zinc finger protein ZBTB10, an inhibitor of Sp1, has been demonstrated. Additionally, botanical compounds were also found to inhibit Sp transcription factors through the miR-27a-ZBTB10-Sp1 axis (<xref rid="b15-or-31-01-0117" ref-type="bibr">15</xref>&#x02013;<xref rid="b17-or-31-01-0117" ref-type="bibr">17</xref>). Therefore, the aim of this study was to investigate the effects of a mixture of quercetin and hyperoside on Sp1, Sp3 and Sp4 expression and the potential involvement of miR-27a in the downregulation of Sp transcription factors in 786-O renal cell carcinoma cells.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Botanical extract</title>
<p>Polyphenolics were extracted from a standardized QH dehydrate supplement (ratio 1:1) in capsule form which was provided by Suzhong Pharmaceutical Co., Ltd. (Taizhou, Jiangsu, China). Polyphenolics were extracted with methanol (50 mg/50 ml) and then centrifuged at room temperature for 10 min at 3,000 rpm to remove inactive and insoluble components. Methanol was evaporated in a rotavapor (B&#x000DC;CHI Labortechnik AG, Flawil, Switzerland) at 40&#x000B0;C. Residual moisture was evaporated in a speedvac concentrator (Thermo Scientific, Waltham, MA, USA) at 43&#x000B0;C. The final QH mixture was stored at &#x02212;80&#x000B0;C and dissolved in dimethyl sulfoxide (DMSO) prior to use.</p></sec>
<sec>
<title>HPLC-PDA analysis</title>
<p>The polyphenolic mixture was analyzed and quantified by retention time and photodiode array (PDA) spectra by HPLC-PDA. The chromatographic separation was performed in an Alliance 2695 system (Waters Corporation, Milford, MA, USA) and carried out in a Discovery C18 column (Supelco Inc., Bellefonte, PA, USA) (250&#x000D7;4.6 mm, 5 <italic>&#x003BC;</italic>m) at room temperature. The chromatographic conditions used were mobile phase A: water/acetic acid (98:2), mobile phase B: acetonitrile/water/acetic acid (68:30:2). A gradient program with 1 ml/min was used as follows: 0 min 100&#x00025;, A; 20 min 60&#x00025;, A; 30 min 30&#x00025;, A; 32 min 0&#x00025;, A; 35 min 100&#x00025;, A. The detection wavelengths were set at 360 and 306 nm for quercetin and hyperoside, respectively. Standard compounds for the identification and quantitative analysis of quercetin and hyperoside were obtained from Acros Organics (Morris Plains, NJ, USA).</p></sec>
<sec>
<title>Oxygen radical absorbance capacity</title>
<p>The antioxidant capacity was determined using the oxygen radical absorbance capacity assay (ORAC) (<xref rid="b22-or-31-01-0117" ref-type="bibr">22</xref>) with fluorescein as the fluorescent probe in a FLUOstar fluorescence microplate reader (485 nm excitation and 538 nm emission; BMG Labtech Inc., Durham, NC, USA). Results were reported in <italic>&#x003BC;</italic>mol of Trolox equivalents/ml.</p></sec>
<sec>
<title>Cell culture</title>
<p>Human clear cell renal carcinoma 786-O cells &#x0005B;American Type Culture Collection (ATCC), Manassas, VA, USA&#x0005D; were cultured in Mc-Coy&#x02019;s medium supplemented with 10&#x00025; fetal bovine serum (FBS) and 1&#x00025; antibiotics (100,000 U/l penicillin and 100 mg/l streptomycin). Cells were maintained in a humidified atmosphere of 95&#x00025; air and 5&#x00025; CO<sub>2</sub> at 37&#x000B0;C. For experiments, cells were seeded in DMEM/F-12 medium with 2.5&#x00025; FBS, and 1&#x00025; antibiotics (100,000 U/l penicillin and 100 mg/l streptomycin). Generation of reactive oxygen species (ROS) was determined using the 2&#x02032;,7&#x02032;-dichlorofluorescein diacetate (DCFH-DA) assay. In summary, 1&#x000D7;10<sup>4</sup> cells/well were seeded in a clear bottom 96-well plate and incubated for 24 h, and then treated with different concentrations of QH (0&#x02013;60 <italic>&#x003BC;</italic>g/ml). After 24 h, cells were washed twice with phosphate-buffered saline (PBS) and incubated with 200 <italic>&#x003BC;</italic>M hydrogen peroxide for 2 h at 37&#x000B0;C. Hydrogen peroxide was removed with PBS washes, and 10 <italic>&#x003BC;</italic>M DCFH-DA diluted in PBS was added to the cells. Next, cells were incubated for 15 min at 37&#x000B0;C, DCFH-DA was removed, and the fluorescence intensity was measured after 15 min at 37&#x000B0;C using a FLUOstar fluorescent microplate reader (485 nm excitation and 538 nm emission).</p></sec>
<sec>
<title>Cell viability</title>
<p>Cells were seeded (3&#x000D7;10<sup>3</sup> cells/well) in a 96-well plate for 24 h, and the growth medium was then replaced with the experimental medium containing various extract concentrations of QH (0&#x02013;60 <italic>&#x003BC;</italic>g/ml). Cell viability was assessed at 48, 72 and 96 h with the CellTiter 96<sup>&#x000AE;</sup> AQueous One Solution Cell Proliferation assay (Promega, Madison, WI, USA) according to the manufacturer&#x02019;s protocol using a FLUOstar microplate reader at 490 nm. The concentration at which cell viability was inhibited by 50&#x00025; (IC<sub>50</sub>) was calculated by sigmoidal nonlinear regression analyses of the percentage of cell inhibition, expressed as a ratio to the control, using GraphPad Prism 5.01 software (GraphPad Software Inc., La Jolla, CA, USA).</p></sec>
<sec>
<title>Cell proliferation</title>
<p>786-O cells (2&#x000D7;10<sup>4</sup> cells/well) were grown in a 24-well plate for 24 h. The growth medium was then replaced with experimental medium containing QH extract concentrations ranging from 0 to 60 <italic>&#x003BC;</italic>g/ml. After 72 h cell proliferation was determined using a cell counter (Beckman Coulter Inc., Fullerton, CA, USA). Cell counts were expressed as a percentage of the control cells.</p></sec>
<sec>
<title>Cleaved caspase-3 activation</title>
<p>Cells were grown (6&#x000D7;10<sup>5</sup> cells/well) for 24 h and then incubated with different QH concentrations (0&#x02013;30 <italic>&#x003BC;</italic>g/ml) for 24 h. Cleaved caspase-3 activation was determined using an ELISA kit (Cell Signaling Technology Inc., Danvers, MA, USA) according to the manufacturer&#x02019;s protocol using a FLUOstar microplate reader at 450 nm.</p></sec>
<sec>
<title>Real-time PCR analysis of miRNA and mRNA</title>
<p>786-O cells were grown (2&#x000D7;10<sup>5</sup> cells/well) in a 6-well plate for 24 h before incubation with different concentrations of QH (0&#x02013;30 <italic>&#x003BC;</italic>g/ml). Total RNA, which contains both mRNA and miRNA, was isolated using the mirVana&#x02122; miRNA Isolation kit (Applied Biosystems Inc., Foster City, CA, USA) following the manufacturer&#x02019;s recommended protocol. Extracted nucleic acid was evaluated for quality and quantity using the NanoDrop<sup>&#x000AE;</sup> ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) at 260 and 280 nm.</p>
<p>SuperScript&#x02122; III First-Strand (Invitrogen, Carlsbad, CA, USA) was used to reverse-transcribe mRNA. TATA-binding protein (TPB) was used as an mRNA endogenous control. For real time PCR (RT-PCR), proprietary primers for Sp3 and Sp4 (Qiagen Inc., Valencia, CA, USA) were used. The following primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA, USA) and used for amplification as follows: TBP (sense, 5&#x02032;-TGC ACA GGA GCC AAG AGT GAA-3&#x02032; and antisense, 5&#x02032;-CAC ATC ACA GCT CCC CAC CA-3&#x02032;), caspase-3 (sense, 5&#x02032;-CTG GAC TGT GGC ATT GAG ACA-3&#x02032; and antisense, 5&#x02032;-CGG CCT CCA CTG GTA TTT TAT G-3&#x02032;), ZBTB10 (sense, 5&#x02032;-GCT GGA TAG TAG TTA TGT TGC-3&#x02032; and antisense, 5&#x02032;-CTG AGT GGT TTG ATG GAC AGA G-3&#x02032;), Sp1 (sense, 5&#x02032;-TCA CCA ATG CCA ATA GCT ACT CA-3&#x02032; and antisense, 5&#x02032;-GAG TTG GTC CCT GAT GAT CCA-3&#x02032;), survivin (sense, 5&#x02032;-CCA TGC AAA GGA AAC CAA CAA T-3&#x02032; and antisense, 5&#x02032;-ATG GCA CGG CGC ACT T-3&#x02032;). RT-PCR for mRNA was performed using the SYBR GreenER qPCR SuperMix (Invitrogen) on a 7900HT Fast Real-Time PCR System (Applied Biosystems Inc.).</p>
<p>The TaqMan<sup>&#x000AE;</sup> MicroRNA Assay for miR-27a and RNU6B (used as the control; Applied Biosystems Inc.) was used to reverse-transcribe mature miRNA following the manufacturer&#x02019;s protocol in a MasterCycler (Eppendorf North America Inc., Westbury, NY, USA). RT-PCR for miRNA was carried out with the TaqMan<sup>&#x000AE;</sup> assay, which contained the forward and reverse primers as well as the TaqMan<sup>&#x000AE;</sup> probe and TaqMan<sup>&#x000AE;</sup> Universal PCR Master mix, No AmpErase<sup>&#x000AE;</sup> UNG (Applied Biosystems Inc.). After completion of RT-PCR, relative quantification for both mRNA and miRNA gene expression was evaluated by using the comparative critical threshold (CT) method. Transfections with 50 and 100 nM miR-27a mimic (Dharmacon, Lafayette, CO, USA) were performed using Lipofectamine 2000 (Invitrogen) for 6 h. After transfection, cells were incubated with 20 <italic>&#x003BC;</italic>g/ml of QH for 24 h.</p></sec>
<sec>
<title>Cell cycle kinetics</title>
<p>Cells were seeded (5&#x000D7;10<sup>5</sup> cells/plate) with medium containing 2.5&#x00025; FBS for 24 h and were subsequently treated with QH (0&#x02013;20 <italic>&#x003BC;</italic>g/ml) for 24 h. Cells were fixed with 90&#x00025; ethanol and stored at &#x02212;20&#x000B0;C. DNA was stained with propidium iodide containing RNAse (0.2 mg/ml) solution and analysis was carried out at 488 nm excitation and 620 nm emission wavelengths on a FACScan flow cytometer (BD Immonunocytometry Systems, San Jos&#x000E9;, CA, USA). The percentage of cells in each cell cycle phase was analyzed using the ModFit LT version 3.2 for Macintosh by Verity Software House (Topsham, ME, USA).</p></sec>
<sec>
<title>Western blotting</title>
<p>Cells were grown (2&#x000D7;10<sup>6</sup> cells/plate) for 24 h and treated with QH (0&#x02013;30 <italic>&#x003BC;</italic>g/ml) for 24 h. Cells were harvested and cell lysates were obtained using a high-salt buffer (1.5 mmol/l MgCl<sub>2</sub>, 500 mmol/l NaCl, 1 mmol/l EGTA, 50 mmol/l HEPES, 10&#x00025; glycerol, 1&#x00025; Triton X-100; adjusted to pH 7.5) supplemented with protease inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Samples were incubated at 100&#x000B0;C for 5 min in 1X Laemmli buffer (0.1&#x00025; bromophenol blue, 175 mM &#x003B2;-mercaptoethanol, 50 mM Tris-HCl, 2&#x00025; SDS). Proteins were separated on a 10&#x00025; (Sp proteins) or 12&#x00025; (survivin) SDS-PAGE at 100 V and transferred to PVDF membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked in nonfat milk in PBS-Tween and incubated with primary antibodies overnight at 4&#x000B0;C. After multiple washing steps, membranes were incubated with secondary antibodies. Membranes were washed and incubated with chemiluminescence substrate (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and proteins were visualized with a Kodak Molecular Imaging System (Carestream Health Inc., Rochester, NY, USA).</p></sec>
<sec>
<title>Statistical analyses</title>
<p>Data from the <italic>in vitro</italic> experiments were analyzed by one-way analysis of variance with JMP 8.0 (SAS Institute, Cary, NC, USA). Differences were deemed significant at p&#x02264;0.05 using a Tukey-Cramer HSD comparison for all pairs. For transfections with the miR-27a mimic, differences were deemed significant at p&#x02264;0.05 using a Student&#x02019;s t-test comparison for all pairs. The analysis of linear (pairwise) correlations was performed where correlations with a p-value &lt;0.05 were deemed significant. Nonlinear modeling of sigmoidal curves for cell viability was performed using GraphPad Prism 5.01 software (GraphPad Software Inc.).</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Chemical composition</title>
<p>The chromatographic profiles (<xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1A and B</xref>) of QH demonstrated the presence of 2 major polyphenols, hyperoside (peak 1) and quercetin (peak 2), respectively, as major ingredients of this botanical supplement. The chemical structures of quercetin and hyperoside are listed in <xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1C and D</xref>. In fact, both quercetin and hyperoside are among the most abundant flavonoids in the routine human diet (<xref rid="b4-or-31-01-0117" ref-type="bibr">4</xref>,<xref rid="b18-or-31-01-0117" ref-type="bibr">18</xref>).</p></sec>
<sec>
<title>Generation of intracellular ROS and ORAC</title>
<p>Intracellular generation of ROS was investigated after 786-O cells were challenged with hydrogen peroxide. QH slightly induced the generation of ROS at low concentrations (0&#x02013;10 <italic>&#x003BC;</italic>g/ml) whereas at concentrations &gt;20 <italic>&#x003BC;</italic>g/ml, generation of ROS was significantly reduced (<xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1E</xref>) by up to 66&#x00025; compared to that of solvent-treated control cells. The antioxidant capacity values (ORAC) (<xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1F</xref>), were significantly increased by all concentrations of QH in a dose-dependent manner.</p></sec>
<sec>
<title>Cell death and cell cycle kinetics</title>
<p>786-O cell viability (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2A</xref>) was significantly decreased by QH in a dose- and time-dependent manner. The IC<sub>50</sub> values were 18.2, 18.7 and 11.8 <italic>&#x003BC;</italic>g/ml at 48, 72 and 96 h, respectively. QH also inhibited cell proliferation after treatment for 72 h (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2B</xref>) illustrated by a decrease in cell counts in a dose-dependent manner. The net number of cells remaining was the combined results of cancer cell proliferation as well as the cytotoxicity of QH. Cell numbers were significantly decreased at all concentrations (3.75&#x02013;60 <italic>&#x003BC;</italic>g/ml), and at 60 <italic>&#x003BC;</italic>g/ml QH cell proliferation was reduced by up to 73&#x00025;.</p>
<p>The effects of QH on cell-cycle progression were determined by fluorescence-activated cell sorting (FACS) analysis (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2C</xref>). There were minor but significant changes in the percentage of cells in different phases of the cell cycle using 2.5, 5, or 10 <italic>&#x003BC;</italic>g/ml of extract. There was a significant G<sub>0</sub>/G<sub>1</sub> to S-phase arrest when compared to the control cells when cells were treated with 20 <italic>&#x003BC;</italic>g/ml of the mixture (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2C</xref>).</p>
<p>Cleaved caspase-3, the activated form, is involved in the execution of apoptosis and was induced up to 1.5-fold even at low concentrations of QH (5 and 10 <italic>&#x003BC;</italic>g/ml) (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2D</xref>). At higher concentrations (20 and 30 <italic>&#x003BC;</italic>g/ml), the induction increased up to 2.3-fold. Poly(ADP-ribose) polymerase 1 (PARP-1) is a substrate for caspase-3 cleavage and produces cleaved PARP-1 (<xref rid="b19-or-31-01-0117" ref-type="bibr">19</xref>). There was an increase in PARP cleavage when cells were treated with QH, as also shown in the densitometry analysis for PARP-1 cleavage/&#x003B2;-actin (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2E</xref>).</p></sec>
<sec>
<title>Modulation of Sp1 transcription factors and dependent genes</title>
<p>Previous studies with several botanical anticancer agents and their synthetic derivatives have demonstrated that these compounds downregulate Sp transcription factors and Sp-regulated genes (<xref rid="b20-or-31-01-0117" ref-type="bibr">20</xref>). The present results showed that QH (5&#x02013;30 <italic>&#x003BC;</italic>g/ml) decreased Sp1, Sp3 and Sp4 mRNA levels, and there was also a parallel decrease in Sp1, Sp3 and Sp4 proteins (<xref rid="f3-or-31-01-0117" ref-type="fig">Fig. 3A&#x02013;C and E</xref>). In addition, QH also decreased expression of survivin protein and mRNA, and these results are consistent with QH-mediated suppression of Sp transcription factors since survivin is an Sp-regulated gene. We also carried out densitometry for the Sp1, Sp3, Sp4, and Sp-regulated genes, expressed as a ratio to &#x003B2;-actin (<xref rid="f3-or-31-01-0117" ref-type="fig">Fig. 3F</xref>).</p>
<p>Previous studies have demonstrated that the inhibition of ZBTB10 expression by miR-27a is at least in part responsible for the increased expression of Sp transcription factors in cancer cells and tumors (<xref rid="b21-or-31-01-0117" ref-type="bibr">21</xref>). In the present study, QH significantly decreased miR-27a (<xref rid="f4-or-31-01-0117" ref-type="fig">Fig. 4A</xref>) and upregulated ZBTB10 mRNA (<xref rid="f4-or-31-01-0117" ref-type="fig">Fig. 4B</xref>), and this was accompanied by decreased Sp proteins and the Sp-regulated gene survivin (<xref rid="f3-or-31-01-0117" ref-type="fig">Fig. 3D and E</xref>). These results are consistent with previous studies regarding the effects of other botanicals and their derivatives on the miR-27a-ZBTB10-Sp1 axis in multiple cancer cell lines (<xref rid="b21-or-31-01-0117" ref-type="bibr">21</xref>). In this study, the overexpression of the miR-27a mimic in 786&#x02013;0 cells increased miR-27a, decreased ZBTB10 and increased Sp1 mRNA levels and this was consistent with the inactivation of endogenous ZBTB10 expressed in these cells (<xref rid="f5-or-31-01-0117" ref-type="fig">Fig. 5A&#x02013;D</xref>). Moreover, the miR-27a mimic also partially reversed QH-induced downregulation of miR-27a, induction of ZBTB10, and downregulation of Sp1 (<xref rid="f5-or-31-01-0117" ref-type="fig">Fig. 5</xref>). Densitometry was performed for Sp-1/&#x003B2;-actin (<xref rid="f5-or-31-01-0117" ref-type="fig">Fig. 5E</xref>).</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<sec>
<title>Generation of intracellular ROS and ORAC</title>
<p>The generation of ROS has been associated with oxidative cellular damage that may be involved in the development of various pathological conditions (<xref rid="b22-or-31-01-0117" ref-type="bibr">22</xref>). The role of ROS in carcinogenesis is complex. Cancer cells tend to have higher constitutive levels of ROS than normal cells, due in part to mutations in nuclear and mitochondrial genes responsible for the electron transport chain and also due to increased metabolism and mitochondrial activity (<xref rid="b23-or-31-01-0117" ref-type="bibr">23</xref>). Elevated levels of ROS may enhance cell proliferation and other events relevant to cancer progression (<xref rid="b23-or-31-01-0117" ref-type="bibr">23</xref>). ROS can also cause DNA damage and oxidation of fatty acids in cellular membrane structures, thereby facilitating mutagenesis and cancer development (<xref rid="b23-or-31-01-0117" ref-type="bibr">23</xref>). However, many anticancer drugs are mitochondro-toxic and induce ROS, which in turn can lead to cancer cell death. Polyphenolics, such as quercetin and hyperoside, have the ability to scavenge free radicals and also induce activation of antioxidant and detoxifying enzymes, thus protecting cells against oxidative damage from carcinogenic compounds (<xref rid="b24-or-31-01-0117" ref-type="bibr">24</xref>). In this study, QH induced a concentration-dependent increase in intracellular antioxidant capacity (<xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1E</xref>) and the intracellular concentration of ROS increased at a low QH concentration (5 <italic>&#x003BC;</italic>g/ml) but decreased at high concentrations (20&#x02013;60 <italic>&#x003BC;</italic>g/ml) (<xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1E</xref>). One possible explanation for this biphasic effect may be the mitochondrotoxic properties of polyphenolics, which also induce ROS, whereas at higher concentrations their antioxidant properties are predominant. Studies with polyphenolics in cancer cells demonstrate their protective effects against oxidative damage in some conditions (<xref rid="b25-or-31-01-0117" ref-type="bibr">25</xref>). In this study, QH induced ROS at lower concentrations, potentially because of the additional formation of radicals, where QH concentrations were too low to have a protective effect. At higher concentrations, QH inhibited the generation of ROS, potentially through scavenging ROS.</p></sec>
<sec>
<title>Cell death and cell cycle kinetics</title>
<p>The anti-proliferative effects of quercetin and hyperoside were previously demonstrated in MOLT-4 leukemia cells, and the combination of resveratrol and quercetin exhibited synergistic effects (<xref rid="b9-or-31-01-0117" ref-type="bibr">9</xref>). Based on the previous study, a combination of quercetin and hyperoside at a ratio of 1:1 was investigated in the present study, resulting in a significant decrease in cell viability and cell proliferation following treatment with QH (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2A and B</xref>). However, it must be considered that for the chosen cell model, another ratio may have been more effective.</p>
<p>It was previously demonstrated that cell cycle arrest is induced by polyphenolics, including resveratrol and quercetin in several cancer cell lines within different phases (<xref rid="b26-or-31-01-0117" ref-type="bibr">26</xref>). Tan <italic>et al</italic>(<xref rid="b27-or-31-01-0117" ref-type="bibr">27</xref>) studied the effect of quercetin on HepG2 cells and found that following treatment with quercetin for 48 h, cells were arrested in the G<sub>0</sub>/G<sub>1</sub> phase. In MOLT-4 leukemia cells, polyphenolic-mediated cell cycle arrest was influenced by the duration of treatment and the type of polyphenolic. In the present study, QH (20 <italic>&#x003BC;</italic>g/ml) decreased the percentage of cells in the S-phase and increased the percentage of cells in the G<sub>0</sub>/G<sub>1</sub> phase, which is consistent with the inhibition of the progression from G<sub>0</sub>/G<sub>1</sub> to S-phase (<xref rid="f2-or-31-01-0117" ref-type="fig">Fig. 2C</xref>).</p>
<p>Caspase-3 is a major executive enzyme in apoptosis and a commonly used indicator for the induction of apoptosis (<xref rid="b28-or-31-01-0117" ref-type="bibr">28</xref>). PARP-1, an abundant chromatin-associated protein, plays an important role in maintaining genome integrity and is cleaved during apoptosis by caspase-3 (<xref rid="b29-or-31-01-0117" ref-type="bibr">29</xref>). Previous studies have demonstrated the effects of quercetin, as well as of a number of other polyphenolics, on caspase-3 and PARP-1 activity (<xref rid="b30-or-31-01-0117" ref-type="bibr">30</xref>). In general, the findings of this study are in concordance with previous studies that found that polyphenolics induce apoptosis through the activation of caspase-3 accompanied by cleavage of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) (<xref rid="b28-or-31-01-0117" ref-type="bibr">28</xref>). Previous studies have shown that resveratrol causes induction of caspase-3 and cleavage of PARP in human articular chondrocytes and myeloid leukemia cells (<xref rid="b28-or-31-01-0117" ref-type="bibr">28</xref>).</p></sec>
<sec>
<title>Modulation of Sp1 transcription factors and dependent genes</title>
<p>Numerous botanical compounds have previously been demonstrated to downregulate Sp transcription factors and Sp-regulated genes (<xref rid="b21-or-31-01-0117" ref-type="bibr">21</xref>). For example, curcumin decreased Sp1, Sp3, and Sp4 levels in bladder and pancreatic cancer cells. The terpenoid betulinic acid also decreased expression of these transcription factors in prostate cancer cells, and synthetic analogs of the triterpenoids oleanolic and glycyrrhetinic acid also exhibited comparable effects (<xref rid="b22-or-31-01-0117" ref-type="bibr">22</xref>). The importance of Sp1 downregulation in terms of the anticancer activity of these compounds is that Sp-regulated genes play an important role in cancer cell and tumor growth (cyclin D1, c-MET and EGFR), survival (NF-&#x003BA;B-p65, survivin and Bcl-2), and angiogenesis (VEGF and its receptors) (<xref rid="b31-or-31-01-0117" ref-type="bibr">31</xref>).</p>
<p>Sp1 overexpression in gastric and pancreatic cancer patients is a negative prognostic factor, as there is evidence that Sp1 exhibits oncogenic properties and plays a role in cell transformation and maintenance of the cancer phenotype (<xref rid="b32-or-31-01-0117" ref-type="bibr">32</xref>). The pathways associated with the induction of high levels of Sp1, Sp3 and Sp4 during transformation are not known. However, our study indicated that at least one mechanism for their elevated expression in cancer cells and tumors was due to inhibition of ZBTB10 expression by miR-27a. ZBTB10 is a translational repressor and binds GC-rich sites to decrease Sp-dependent trans-activation (<xref rid="b33-or-31-01-0117" ref-type="bibr">33</xref>). In the present study, the effects of QH were not dose-dependent for miR-27a itself, but for ZBTB10 (<xref rid="f4-or-31-01-0117" ref-type="fig">Fig. 4A and B</xref>). Many miRNAs play important roles in carcinogenesis, with either oncogenic or tumor-suppressing activities (<xref rid="b34-or-31-01-0117" ref-type="bibr">34</xref>). The overexpression of oncogenic miRNAs has been demonstrated in several cancer cell lines (<xref rid="b35-or-31-01-0117" ref-type="bibr">35</xref>). In previous studies, miR-27a expression was increased in 6 breast cancer cell lines and also in colon cancer cells (<xref rid="b35-or-31-01-0117" ref-type="bibr">35</xref>,<xref rid="b36-or-31-01-0117" ref-type="bibr">36</xref>). In the present study, a mimic for miR-27a partially reversed the effects of the extracts on Sp1 protein; however these effects were not significant for Sp1 mRNA.</p>
<p>Results from this study for the first time demonstrated that apoptosis induced by QH and inhibition of HT-29 cell growth was associated with decreased expression of Sp1, Sp3, Sp4, and Sp-regulated survivin. These latter responses were paralleled by perturbation of the miR-27a-ZBTB10 axis, resulting in the induction of ZBTB10, a potent Sp-repressor gene (<xref rid="b36-or-31-01-0117" ref-type="bibr">36</xref>). These effects of QH on miR-27a-ZBTB10 were observed at concentrations of QH that decreased ROS in the HT-29 cells (<xref rid="f1-or-31-01-0117" ref-type="fig">Fig. 1E</xref>), whereas previous studies with curcumin and the synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDOMe) showed that their effects on miR-27a-ZBTB10 were dependent on the generation of ROS (<xref rid="b36-or-31-01-0117" ref-type="bibr">36</xref>). Ongoing studies in our laboratory are focused on mechanisms of ROS-independent downregulation of miR-27a by QH and other anticancer agents as this pathway plays an important role in the anticancer activity of botanicals and their derivates.</p>
<p>In conclusion, the present results revealed that a combination of quercetin and hyperoside had cytotoxic effects on colon cancer cells, resulting in apoptosis. Interactions of QH and the miR-27a-ZBTB10-Sp1 axis were identified as one possible underlying mechanism. Further studies are needed to assess the role of miR-27a and its clinical relevance in the anticancer effects exhibited by botanicals.</p></sec></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was partially supported by grants from the National Natural Science Foundation of China (nos. 81000311 and 81270831).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-31-01-0117"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>H</given-names></name><name><surname>Miller</surname><given-names>JS</given-names></name><name><surname>Fajardo</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system</article-title><source>Pathol Int</source><volume>60</volume><fpage>1</fpage><lpage>8</lpage><year>2010</year></element-citation></ref>
<ref id="b2-or-31-01-0117"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zisman</surname><given-names>A</given-names></name><name><surname>Pantuck</surname><given-names>AJ</given-names></name><name><surname>Wieder</surname><given-names>J</given-names></name><etal/></person-group><article-title>Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma</article-title><source>J Clin Oncol</source><volume>20</volume><fpage>4559</fpage><lpage>4566</lpage><year>2002</year></element-citation></ref>
<ref id="b3-or-31-01-0117"><label>3</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Eble</surname><given-names>JN</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name><name><surname>Sesterhenn</surname><given-names>I</given-names></name></person-group><article-title>World Health Organization Classification of Tumors</article-title><source>Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs</source><publisher-name>IARC Press</publisher-name><publisher-loc>Lyon</publisher-loc><year>2005</year></element-citation></ref>
<ref id="b4-or-31-01-0117"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodoratou</surname><given-names>E</given-names></name><name><surname>Kyle</surname><given-names>J</given-names></name><name><surname>Cetnarskyj</surname><given-names>R</given-names></name><etal/></person-group><article-title>Dietary flavonoids and the risk of colorectal cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>16</volume><fpage>684</fpage><lpage>693</lpage><year>2007</year></element-citation></ref>
<ref id="b5-or-31-01-0117"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Apoptotic effect of red wine polyphenols on human colon cancer SNU-C4 cells</article-title><source>Food Chem Toxicol</source><volume>44</volume><fpage>898</fpage><lpage>902</lpage><year>2006</year></element-citation></ref>
<ref id="b6-or-31-01-0117"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens-Talcott</surname><given-names>SU</given-names></name><name><surname>Percival</surname><given-names>SS</given-names></name></person-group><article-title>Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells</article-title><source>Cancer Lett</source><volume>218</volume><fpage>141</fpage><lpage>151</lpage><year>2005</year></element-citation></ref>
<ref id="b7-or-31-01-0117"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Protective effects of leaf extract of <italic>Zanthoxylum ailanthoides</italic> on oxidation of low-density lipoprotein and accumulation of lipid in differentiated THP-1 cells</article-title><source>Food Chem Toxicol</source><volume>47</volume><fpage>1265</fpage><lpage>1271</lpage><year>2009</year></element-citation></ref>
<ref id="b8-or-31-01-0117"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>LL</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Molecular mechanisms of celery seed extract induced apoptosis via S phase cell cycle arrest in the BGC-823 human stomach cancer cell line</article-title><source>Asian Pac J Cancer Prev</source><volume>12</volume><fpage>2601</fpage><lpage>2606</lpage><year>2011</year></element-citation></ref>
<ref id="b9-or-31-01-0117"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens-Talcott</surname><given-names>SU</given-names></name><name><surname>Talcott</surname><given-names>ST</given-names></name><name><surname>Percival</surname><given-names>SS</given-names></name></person-group><article-title>Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells</article-title><source>J Nutr</source><volume>133</volume><fpage>2669</fpage><lpage>2674</lpage><year>2003</year></element-citation></ref>
<ref id="b10-or-31-01-0117"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Srivastava</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53</article-title><source>PLoS One</source><volume>6</volume><fpage>e23395</fpage><year>2011</year></element-citation></ref>
<ref id="b11-or-31-01-0117"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>RK</given-names></name><name><surname>Tang</surname><given-names>SN</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells</article-title><source>Front Biosci (Elite Ed)</source><volume>3</volume><fpage>515</fpage><lpage>528</lpage><year>2011</year></element-citation></ref>
<ref id="b12-or-31-01-0117"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>SN</given-names></name><name><surname>Singh</surname><given-names>C</given-names></name><name><surname>Nall</surname><given-names>D</given-names></name><etal/></person-group><article-title>The dietary bioflavonoid quercetin synergizes with epigallocatechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition</article-title><source>J Mol Signal</source><volume>5</volume><fpage>14</fpage><year>2010</year></element-citation></ref>
<ref id="b13-or-31-01-0117"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadalapaka</surname><given-names>G</given-names></name><name><surname>Jutooru</surname><given-names>I</given-names></name><name><surname>Burghardt</surname><given-names>R</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells</article-title><source>Mol Cancer Res</source><volume>8</volume><fpage>739</fpage><lpage>750</lpage><year>2010</year></element-citation></ref>
<ref id="b14-or-31-01-0117"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chadalapaka</surname><given-names>G</given-names></name><name><surname>Jutooru</surname><given-names>I</given-names></name><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Curcumin decreases specificity protein expression in bladder cancer cells</article-title><source>Cancer Res</source><volume>68</volume><fpage>5345</fpage><lpage>5354</lpage><year>2008</year></element-citation></ref>
<ref id="b15-or-31-01-0117"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Papineni</surname><given-names>S</given-names></name><name><surname>Abdelrahim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18&#x003B2;-olean-1,12-dien-30-oate in colon cancer cells</article-title><source>Int J Cancer</source><volume>125</volume><fpage>1965</fpage><lpage>1974</lpage><year>2009</year></element-citation></ref>
<ref id="b16-or-31-01-0117"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutooru</surname><given-names>I</given-names></name><name><surname>Chadalapaka</surname><given-names>G</given-names></name><name><surname>Abdelrahim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a</article-title><source>Mol Pharmacol</source><volume>78</volume><fpage>226</fpage><lpage>236</lpage><year>2010</year></element-citation></ref>
<ref id="b17-or-31-01-0117"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jutooru</surname><given-names>I</given-names></name><name><surname>Chadalapaka</surname><given-names>G</given-names></name><name><surname>Lei</surname><given-names>P</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>Inhibition of NF-&#x003BA;B and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation</article-title><source>J Biol Chem</source><volume>285</volume><fpage>25332</fpage><lpage>25344</lpage><year>2011</year></element-citation></ref>
<ref id="b18-or-31-01-0117"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fr&#x000E9;mont</surname><given-names>L</given-names></name></person-group><article-title>Biological effects of resveratrol (Review)</article-title><source>Life Sci</source><volume>66</volume><fpage>663</fpage><lpage>673</lpage><year>2000</year></element-citation></ref>
<ref id="b19-or-31-01-0117"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brauns</surname><given-names>SC</given-names></name><name><surname>Dealtry</surname><given-names>G</given-names></name><name><surname>Milne</surname><given-names>P</given-names></name><etal/></person-group><article-title>Caspase-3 activation and induction of PARP cleavage by cyclic dipeptide Cyclo(Phe-Pro) in HT-29 cells</article-title><source>Anticancer Res</source><volume>25</volume><fpage>4197</fpage><lpage>4202</lpage><year>2005</year></element-citation></ref>
<ref id="b20-or-31-01-0117"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Velalar</surname><given-names>CN</given-names></name><name><surname>Ruan</surname><given-names>R</given-names></name></person-group><article-title>Effects of epigallocatechin-3-gallate on mitochondrial integrity and antioxidative enzyme activity in the aging process of human fibroblast</article-title><source>Free Rad Biol Med</source><volume>44</volume><fpage>1032</fpage><lpage>1041</lpage><year>2008</year></element-citation></ref>
<ref id="b21-or-31-01-0117"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens-Talcott</surname><given-names>SU</given-names></name><name><surname>Chintharlapalli</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>MR</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G<sub>2</sub>-M checkpoint in MDA-MB-231 breast cancer cells</article-title><source>Cancer Res</source><volume>67</volume><fpage>11001</fpage><lpage>11011</lpage><year>2007</year></element-citation></ref>
<ref id="b22-or-31-01-0117"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fresco</surname><given-names>P</given-names></name><name><surname>Borges</surname><given-names>F</given-names></name><name><surname>Diniz</surname><given-names>C</given-names></name><name><surname>Marques</surname><given-names>MP</given-names></name></person-group><article-title>New insights on the anticancer properties of dietary polyphenols</article-title><source>Med Res Rev</source><volume>26</volume><fpage>747</fpage><lpage>766</lpage><year>2006</year></element-citation></ref>
<ref id="b23-or-31-01-0117"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacker</surname><given-names>PT</given-names></name></person-group><article-title>Reactive oxygen species in cancer cells: live by the sword, die by the sword</article-title><source>Cancer Cell</source><volume>10</volume><fpage>175</fpage><lpage>176</lpage><year>2006</year></element-citation></ref>
<ref id="b24-or-31-01-0117"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiander</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>H</given-names></name></person-group><article-title>Dietary ortho phenols that induce glutathione S-transferase and increase the resistance of cells to hydrogen peroxide are potential cancer chemopreventives that act by two mechanisms: the alleviation of oxidative stress and the detoxification of mutagenic xenobiotics</article-title><source>Cancer Lett</source><volume>156</volume><fpage>117</fpage><lpage>124</lpage><year>2000</year></element-citation></ref>
<ref id="b25-or-31-01-0117"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>SC</given-names></name><name><surname>Lu</surname><given-names>JH</given-names></name><name><surname>Kuo</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Crude extracts of <italic>Solanum lyratum</italic> induced cytotoxicity and apoptosis in a human colon adenocarcinoma cell line (colo 205)</article-title><source>Anticancer Res</source><volume>28</volume><fpage>1045</fpage><lpage>1054</lpage><year>2008</year></element-citation></ref>
<ref id="b26-or-31-01-0117"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlachterman</surname><given-names>A</given-names></name><name><surname>Valle</surname><given-names>F</given-names></name><name><surname>Wall</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model</article-title><source>Transl Oncol</source><volume>1</volume><fpage>19</fpage><lpage>27</lpage><year>2008</year></element-citation></ref>
<ref id="b27-or-31-01-0117"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title>Regulation of survivin and Bcl-2 in HepG2 cell apoptosis induced by quercetin</article-title><source>Chem Biodivers</source><volume>6</volume><fpage>1101</fpage><lpage>1110</lpage><year>2009</year></element-citation></ref>
<ref id="b28-or-31-01-0117"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shakibaei</surname><given-names>M</given-names></name><name><surname>John</surname><given-names>T</given-names></name><name><surname>Seifarth</surname><given-names>C</given-names></name><name><surname>Mobasheri</surname><given-names>A</given-names></name></person-group><article-title>Resveratrol inhibits IL-1&#x003B2;-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes <italic>in vitro</italic></article-title><source>Ann NY Acad Sci</source><volume>1095</volume><fpage>554</fpage><lpage>563</lpage><year>2007</year></element-citation></ref>
<ref id="b29-or-31-01-0117"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Stingl</surname><given-names>L</given-names></name><name><surname>Morrison</surname><given-names>C</given-names></name><etal/></person-group><article-title>PARP is important for genomic stability but dispensable in apoptosis</article-title><source>Genes Dev</source><volume>11</volume><fpage>2347</fpage><lpage>2358</lpage><year>1997</year></element-citation></ref>
<ref id="b30-or-31-01-0117"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CP</given-names></name><name><surname>Lin</surname><given-names>YH</given-names></name><name><surname>Chou</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Mechanisms of grape seed procyanidin-induced apoptosis in colorectal carcinoma cells</article-title><source>Anticancer Res</source><volume>29</volume><fpage>283</fpage><lpage>289</lpage><year>2009</year></element-citation></ref>
<ref id="b31-or-31-01-0117"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>CK</given-names></name><name><surname>Oh</surname><given-names>E</given-names></name><etal/></person-group><article-title>Low SP1 expression differentially affects intestinal-type compared with diffuse-type gastric adenocarcinoma</article-title><source>PLoS One</source><volume>8</volume><fpage>e55522</fpage><year>2013</year></element-citation></ref>
<ref id="b32-or-31-01-0117"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>K</given-names></name><name><surname>Onion</surname><given-names>D</given-names></name><name><surname>Kumari</surname><given-names>R</given-names></name><etal/></person-group><article-title>Elevated SP-1 transcription factor expression and activity drives basal and hypoxia-induced vascular endothelial growth factor (VEGF) expression in non-small cell lung cancer</article-title><source>J Biol Chem</source><volume>287</volume><fpage>39967</fpage><lpage>39981</lpage><year>2012</year></element-citation></ref>
<ref id="b33-or-31-01-0117"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Chadalapaka</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>SO</given-names></name><etal/></person-group><article-title>Identification of oncogenic microRNA-17&#x02013;92/ZBTB4/specificity protein axis in breast cancer</article-title><source>Oncogene</source><volume>31</volume><fpage>1034</fpage><lpage>1044</lpage><year>2012</year></element-citation></ref>
<ref id="b34-or-31-01-0117"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynam-Lennon</surname><given-names>N</given-names></name><name><surname>Maher</surname><given-names>SG</given-names></name><name><surname>Reynolds</surname><given-names>JV</given-names></name></person-group><article-title>The roles of microRNA in cancer and apoptosis (Review)</article-title><source>Biol Rev Camb Philos Soc</source><volume>84</volume><fpage>55</fpage><lpage>71</lpage><year>2009</year></element-citation></ref>
<ref id="b35-or-31-01-0117"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><etal/></person-group><article-title>MiR-27 as a prognostic marker for breast cancer progression and patient survival</article-title><source>PLoS One</source><volume>7</volume><fpage>e51702</fpage><year>2012</year></element-citation></ref>
<ref id="b36-or-31-01-0117"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noratto</surname><given-names>GD</given-names></name><name><surname>Jutooru</surname><given-names>I</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name><etal/></person-group><article-title>The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen species-induced disruption of the microRNA-27a-ZBTB10-Sp axis</article-title><source>Mol Nutr Food Res</source><volume>57</volume><fpage>1638</fpage><lpage>1648</lpage><year>2013</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-31-01-0117" position="float">
<label>Figure 1</label>
<caption>
<p>Chromatographic profile of quercetin and hyperoside (QH) in combination. (A) Stilbenes; (B) flavonols. Peak assignments: 1, hyperoside; 2, quercetin. (C) Chemical structure of hyperoside. (D) Chemical structure of quercetin. (E) Hydrogen peroxide-induced generation of reactive oxygen species (ROS) in 786-O cells treated with QH. (F) Oxygen radical absorbance capacity assay (ORAC) values for the 786-O cell supernatant following treatment with QH after 24 h. Bars of the histograms represent mean &#x000B1; SEM; n&#x0003D;3. Bars with different letters indicate significantly different results (least significant difference test, p&lt;0.05).</p></caption>
<graphic xlink:href="OR-31-01-0117-g00.gif"/></fig>
<fig id="f2-or-31-01-0117" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of quercetin and hyperoside (QH) on cell death in 786-O cells. (A) Cell viability of 786-O cells treated with QH after 48, 72 and 96 h of incubation. (B) Cell proliferation of 786-O cells after 72 h of incubation. (C) Cell cycle kinetics in 786-O cells treated with the QH mixture for 24 h. (D) Protein levels of cleaved caspase-3 at 24 h. (E) Protein expression of poly(ADP-ribose) polymerase-1 (PARP-1) and cleaved PARP (Asp214) at 24 h. (F) Protein expression of cleaved PARP normalized to &#x003B2;-actin. Values represent mean &#x000B1; SEM; n&#x0003D;3. Bars with different letters indicate significantly different results (least significant difference test, p&lt;0.05).</p></caption>
<graphic xlink:href="OR-31-01-0117-g01.gif"/></fig>
<fig id="f3-or-31-01-0117" position="float">
<label>Figure 3</label>
<caption>
<p>Expression of specificity protein (Sp)1, Sp3, Sp4 and survivin in 786-O cells after 24 h of incubation with quercetin and hyperoside (QH). (A) mRNA expression of Sp1. (B) mRNA expression of Sp3. (C) mRNA expression of Sp4. (D) mRNA expression of survivin. (E) Protein expression of Sp proteins and survivin. (F) Protein expression of Sp proteins and survivin normalized to &#x003B2;-actin. Bars represent mean &#x000B1; SEM, n&#x0003D;3. Bars with different letters indicate significantly different results (least significant difference test, p&lt;0.05).</p></caption>
<graphic xlink:href="OR-31-01-0117-g02.gif"/></fig>
<fig id="f4-or-31-01-0117" position="float">
<label>Figure 4</label>
<caption>
<p>Expression of microRNA-27a (miR-27a) and ZBTB10 in 786-O cells 24 h after incubation with quercetin and hyperoside (QH). (A) Expression of miR-27a. (B) mRNA expression of ZTB10. Bars represent mean &#x000B1; SEM; n&#x0003D;3. Bars with different letters indicate significantly different results (least significant difference test, p&lt;0.05).</p></caption>
<graphic xlink:href="OR-31-01-0117-g03.gif"/></fig>
<fig id="f5-or-31-01-0117" position="float">
<label>Figure 5</label>
<caption>
<p>Effects of microRNA-27a (miR-27a) mimic on the miR-27a-ZBTB10-Sp1 axis after 24 h. (A) Expression of miR-27a after transfection with miR-27a mimic in HT-29 cells. (B) mRNA expression of ZBTB10. (C) mRNA expression of specificity protein (Sp)1. (D) Protein expression of Sp1 protein after transfection with miR-27a mimic. (E) Protein expression of Sp1 was normalized to &#x003B2;-actin. Bars represent means &#x000B1; SEM; n&#x0003D;3. Bars with different letters indicate significantly different results (least significant difference test, p&lt;0.05).</p></caption>
<graphic xlink:href="OR-31-01-0117-g04.gif"/></fig></floats-group></article>
